Company profile
Savara Inc
NASDAQ:SVRABiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| MOLGRAMOSTIM | phase3 | — | 5 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03181932 | phase3 | completed | 2017-09-20 | 2020-07-28 | Savara Inc. | AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic Fibrosis |
| NCT04544293 | phase3 | active_not_recruiting | 2021-05-19 | 2023-11-30 | Savara Inc. | Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) |
| NCT01746095 | phase2 | completed | 2013-03-01 | 2014-11-01 | Savara Inc. | Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients |
| NCT02702180 | phase2 | completed | 2016-03-21 | 2019-04-19 | Savara Inc. | Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis |
| NCT02468908 | phase1 | completed | 2015-05-01 | 2015-10-01 | Savara Inc. | Inhaled Molgramostim (rhGM-CSF) in Healthy Adult Subjects |
FDA applications (0)
No records yet.